Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.


Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:REGN
17/05/202418:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
17/05/202414:45GlobeNewswire Inc.More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
14/05/202417:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/05/202402:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/05/202407:00GlobeNewswire Inc.Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 WeeksNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/05/202417:05GlobeNewswire Inc.Regeneron Announces Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/05/202407:30GlobeNewswire Inc.Regeneron Reports First Quarter 2024 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
29/04/202408:00GlobeNewswire Inc.EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
25/04/202408:00GlobeNewswire Inc.Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
24/04/202411:05GlobeNewswire Inc.Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCONASDAQ:REGNRegeneron Pharmaceuticals Inc
22/04/202418:54GlobeNewswire Inc.Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/04/202408:18IH Market NewsEricsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More NewsNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/04/202408:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/04/202417:00GlobeNewswire Inc.Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/04/202417:05GlobeNewswire Inc.Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
25/03/202408:00GlobeNewswire Inc.Regeneron Provides Update on Biologics License Application for OdronextamabNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/03/202400:55PR Newswire (US)High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical OptimizationNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/03/202408:00GlobeNewswire Inc.Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High CholesterolNASDAQ:REGNRegeneron Pharmaceuticals Inc
08/03/202409:00GlobeNewswire Inc.EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The LancetNASDAQ:REGNRegeneron Pharmaceuticals Inc
23/02/202403:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 InflammationNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/02/202409:00GlobeNewswire Inc.Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority ReviewNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/02/202402:59GlobeNewswire Inc.Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)NASDAQ:REGNRegeneron Pharmaceuticals Inc
09/02/202420:19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/02/202418:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/02/202411:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202409:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202408:30GlobeNewswire Inc.Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202408:00GlobeNewswire Inc.Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/01/202411:25AllPennyStocks.comBiotech Shares Soar Premarket On Sale Of R&D AssetsNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/01/202409:00GlobeNewswire Inc.Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical ProgramsNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:REGN

Seu Histórico Recente